Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Slides:

Advertisements

Similar presentations

Lipid Transport and Storage Medical Biochemistry Lectures #54 and #55.

Advertisements

Diet Study for Nonalcoholic Fatty Liver Disease Lab meeting.

Samir Parekh, Frank A. Anania Gastroenterology

Insulin action is reduced in obesity

THE MANY FUNCTIONS OF INSULIN IN LIPID METABOLISM

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Volume 148, Issue 4, Pages (April 2015)

Lipids in Liver Disease: Looking Beyond Steatosis

Figure 2 Hepatic action of functional foods and supplements

Figure 5 Dendritic cells in liver inflammation

Figure 4 Activation of clopidogrel via cytochrome P450

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Patients cured of HCV infection

Figure 1 Pathophysiological aspects of insulin

Figure 5 Lipid droplet consumption

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Worldwide incidence of CCA

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Biosimilar development process

Samir Parekh, Frank A. Anania Gastroenterology

Figure 2 Effect of PPIs on gastric physiology

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 4 Giant lipid droplet formation

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 ER stress and hepatic steatosis: a vicious cycle

Figure 6 Combination therapy for HCC

Figure 1 Definition and concept of ACLF

Figure 2 Switching of biologic agents and biosimilars

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

to the liver and promote patient-derived xenograft tumour growth

Figure 1 Environmental factors contributing to IBD pathogenesis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 Clinical algorithms in the management of NASH and diabetes mellitus Figure 3 | Clinical algorithms in the management of NASH and diabetes mellitus.

Figure 2 13C-octanoic acid gastric emptying breath test

Figure 3 Serotonin influences many peripheral tissues

in the UK (1961–2012), France (1961–2014) and Italy (1961–2010)

Figure 3 Mechanisms of NS5B-mediated RNA synthesis

Sugar, Sugar Not So Sweet for the Liver

Figure 3 Lipid droplet formation and expansion

Figure 1 Key mechanistic pathways involved in the gut–liver axis in NAFLD progression Figure 1 | Key mechanistic pathways involved in the gut–liver axis.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 6 Possible therapeutic targets to decrease hepatic steatosis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Schematic of normal and abnormal liver regeneration

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 Strategies to improve liver regeneration

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 5 Systems biological model of IBS

Nat. Rev. Endocrinol. doi: /nrendo

The genetics of alcohol dependence and alcohol-related liver disease

Figure 2 Lipid metabolism and metabolism-disrupting chemicals.

Figure 1 The major pathways of lipid metabolism

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Volume 134, Issue 2, Pages (February 2008)

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Lifelong influences on the gut microbiome from

Figure 1 NAFLD pathogenesis

Assembly and secretion of apoB100- containing lipoproteins

Lipids in Liver Disease: Looking Beyond Steatosis

Figure 2 Classifications and appearance of CCAs

Knockdown of MPST weakens JNK phosphorylation, ameliorates hepatic oxidative stress and suppresses the release of MCP-1. Knockdown of MPST weakens JNK.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Thyroid hormone effects on hepatic lipid metabolism

Volume 135, Issue 6, Pages (December 2008)

Presentation transcript:

Nat. Rev. Gastroenterol. Hepatol. doi:10.1038/nrgastro.2017.32 Figure 1 Hepatic steatosis results from an imbalance in lipid storage and lipolysis or secretion Figure 1 | Hepatic steatosis results from an imbalance in lipid storage and lipolysis or secretion. Hepatic steatosis can result from different processes: increased fatty acid (FA) uptake, de novo lipogenesis and triglyceride synthesis combined with lipid droplet (LD) biogenesis or growth; decreased LD catabolism (including decreased fatty acid oxidation); or impaired triglyceride or very-low-density lipoprotein (VLDL) secretion. Factors associated with these processes are listed in the figures, those that upregulate steatosis (green boxes) and those that downregulate steatosis (orange boxes). Gluchowski, N. L. et al. (2017) Lipid droplets and liver disease: from basic biology to clinical implications Nat. Rev. Gastroenterol. Hepatol. doi:10.1038/nrgastro.2017.32